FY2026 EPS Forecast for Pharming Group Lowered by Analyst

Key Points

• HC Wainwright cut Pharming Group’s FY2026 EPS forecast to $0.25 from $0.45, below the $0.32 consensus estimate, while maintaining a Buy rating and $37 price target.
• Pharming reported quarterly EPS of $0.30, beating the $0.21 consensus, on revenue of $117.6 million. However, analysts’ consensus view remains Hold, with an average price target of $38.67.
• The stock opened at $12.26 and trades at a high valuation of roughly 102 times earnings; MAC Alpha Capital Management recently acquired a 3.03% stake worth approximately $29.8 million.

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Free Report) - Equities researchers at HC Wainwright reduced their FY2026 EPS estimates for shares of Pharming Group in a research report issued on Tuesday, October 27th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings per share of $0.25 for the year, down from their prior forecast of $0.45. HC Wainwright currently has a "Buy" rating and a $37.00 price objective on the stock. The consensus estimate for Pharming Group's current full-year earnings is $0.32 per share.

PHAR has been the topic of a number of other reports. Weiss Ratings raised shares of Pharming Group from a "sell (d)" rating to a "sell (d+)" rating in a research report on Tuesday. Canaccord Genuity Group set a $38.00 price target on Pharming Group in a research note on Wednesday, September 23rd. Zacks Research upgraded Pharming Group from a "strong sell" rating to a "hold" rating in a report on Friday, October 23rd. Oppenheimer reaffirmed an "outperform" rating on shares of Pharming Group in a research report on Wednesday. Finally, Wall Street Zen raised Pharming Group to a "hold" rating in a research report on Saturday, October 24th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Pharming Group has a consensus rating of "Hold" and an average price target of $38.67.

Pharming Group Stock Performance

NASDAQ:PHAR opened at $12.26 on Thursday. Pharming Group has a fifty-two week low of $9.11 and a fifty-two week high of $21.34. The firm has a market capitalization of $867.74 million, a PE ratio of 102.17 and a beta of -0.05. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.31 and a current ratio of 3.01. The stock's fifty day moving average is $10.70 and its 200 day moving average is $13.86.

Pharming Group (NASDAQ:PHAR - Get Free Report) last posted its earnings results on Tuesday, October 27th. The company reported $0.30 earnings per share for the quarter, topping analysts' consensus estimates of $0.21 by $0.09. Pharming Group had a net margin of 2.51% and a return on equity of 3.40%. The firm had revenue of $117.60 million for the quarter, compared to the consensus estimate of $117.60 million.

Institutional Investors Weigh In On Pharming Group

A hedge fund recently bought a new stake in Pharming Group stock. MAC Alpha Capital Management LP acquired a new stake in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 2,148,144 shares of the company's stock, valued at approximately $29,838,000. Pharming Group accounts for approximately 6.0% of MAC Alpha Capital Management LP's holdings, making the stock its 2nd largest position. MAC Alpha Capital Management LP owned about 3.03% of Pharming Group as of its most recent filing with the Securities and Exchange Commission. 0.03% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Pharming Group

Here are the key news stories impacting Pharming Group this week:

• Positive Sentiment: Strong Q3 performance: Third-quarter revenue increased 21% year over year to $117.6 million, matching expectations, while operating profit rose 89% to $29.9 million. Earnings of $0.30 per share exceeded the $0.15 consensus estimate. Pharming Group third-quarter 2026 financial results
• Positive Sentiment: Both key products grew: Ruconest revenue rose 14% to $93.8 million as demand stabilized, while Joenja revenue jumped 58% to $23.8 million on strong U.S. and international demand. Joenja is also expanding through a U.S. pediatric label and launches in Germany and Japan. Joenja gains momentum and Ruconest returns to growth
• Positive Sentiment: Financial position strengthened: Pharming generated $32.4 million in quarterly operating cash flow, ending the period with $190.9 million in cash. Management tightened its 2026 revenue outlook to $380 million–$390 million from $375 million–$395 million, signaling greater confidence in the forecast.
• Positive Sentiment: Analyst outlook improved: HC Wainwright maintained a Buy rating and $37 price target, while raising its FY2027 EPS forecast to $0.59 from $0.56. The target implies substantial upside relative to recent trading levels. Pharming Q3 2026 earnings call transcript
• Neutral Sentiment: Upcoming catalyst: Pharming expects topline data in November from a Phase II trial of leniolisib in a broader common variable immunodeficiency (CVID) population. Positive data could support Joenja’s expansion, while disappointing results would create downside risk. Pharming Q3 revenue and CVID data
• Negative Sentiment: Near-term earnings remain uneven: HC Wainwright expects a $0.01-per-share loss in the fourth quarter, and PHAR’s valuation remains demanding at roughly 102 times earnings, increasing sensitivity to clinical or commercial setbacks.

Pharming Group Company Profile

Pharming Group N.V. is a biopharmaceutical company headquartered in Leiden, the Netherlands. The company develops and commercializes medicines for rare diseases and operates internationally, serving patients and healthcare providers in North America, Europe and other selected markets.

Pharming's principal product is Ruconest, a recombinant C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, a rare genetic disorder that can cause potentially serious swelling. The company also markets Joenja (leniolisib), an oral treatment for activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.